Reaction
Microangiopathy reporting signals
As of the last recalculation, Microangiopathy appears in 923 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is CICLESONIDE (PRR 91.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ciclesonide | 52 | 91.2 | 91.5 |
| Goserelin | 51 | 90.6 | 91.0 |
| Bicalutamide | 50 | 78.2 | 78.4 |
| Sodium Bicarbonate | 45 | 45.8 | 45.9 |
| Sodium Bicarbonate Injection, | 45 | 45.8 | 45.9 |
| Salmeterol Xinafoate | 14 | 37.2 | 37.2 |
| Busulfan | 23 | 33.8 | 33.8 |
| Calcium Gluconate | 16 | 30.5 | 30.5 |
| Carboxymethylcellulose Sodium | 12 | 29.2 | 29.2 |
| Basiliximab | 13 | 25.3 | 25.3 |
| Fludarabine Phosphate | 40 | 23.9 | 24.0 |
| Thiotepa | 9 | 21.5 | 21.5 |
| Alemtuzumab | 18 | 21.4 | 21.4 |
| Fluticasone Propionate And Salmeterol Xinafoate | 50 | 19.8 | 19.8 |
| Ganciclovir Sodium | 9 | 19.4 | 19.4 |
| Melphalan Hydrochloride | 20 | 18.4 | 18.4 |
| Ganciclovir | 8 | 17.8 | 17.8 |
| Mepolizumab | 29 | 13.6 | 13.6 |
| Cyclophosphamide Injection, Solution | 94 | 13.2 | 13.2 |
| Cyclophosphamide | 94 | 13.2 | 13.2 |
| Cyclophosphamide For Injection | 94 | 13.2 | 13.2 |
| Bevacizumab | 67 | 13.1 | 13.1 |
| Ranolazine | 6 | 13.0 | 13.0 |
| Brentuximab Vedotin | 5 | 11.1 | 11.1 |
| Eculizumab | 25 | 10.6 | 10.6 |
| Remdesivir | 6 | 10.2 | 10.2 |
| Carfilzomib | 12 | 9.7 | 9.7 |